TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28692301
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D3
Study: 23935398
Drug: Cilnidipine (10.27
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilnidipine (10.27 ± 4.13 mg/day)
Study: 23935398
Drug: Amlodipine (4.87
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (4.87 ± 2.08 mg/day)
Study: 17983434
Drug: Oxybutynin transdermal
Normalized name: oxyBUTYnin Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin transdermal system (OXY‐TDS) 3.9 mg/day
Study: 15725084
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose melphalan-prednisone (MP)
Study: 4052143
Drug: Flupirtine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupirtine (3 X 100 mg on the previous day and 100 mg before the test)
Study: 4052143
Drug: Diazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (10 mg perorally 2 days before and 5 mg perorally on the preceding day)
Study: 29265699
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green administration at 3, 6, 9, 12, 15, 18, and 24 hours before surgery
Study: 11064964
Drug: Waiting list,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list, no-treatment or placebo control group
Study: 8520059
Drug: Human leukocyte
Normalized name: Human leukocyte antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human leukocyte interferon-alpha cream (2 x 10(6) IU/g)
Study: 8457025
Drug: Ipratropium 40
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium 40 micrograms four times daily
Study: 3092392
Drug: Glibenclamide and
Normalized name: Glibenclamide and metformin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide and metformin
Study: 20465593
Drug: Wireless motility
Normalized name: careless weed pollen extract
DrugBank: Amaranthus palmeri pollen (DB10459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wireless motility capsule (WMC)
Study: 22572600
Drug: Wireless motility
Normalized name: careless weed pollen extract
DrugBank: Amaranthus palmeri pollen (DB10459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wireless motility capsule (WMC) and Radioopaque markers (ROM)
Study: 16434463
Drug: 20% lipid/heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% lipid/heparin infusion
Study: 16434463
Drug: saline/heparin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline/heparin infusion
Study: 12208800
Drug: Tranilast (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranilast (300 and 450 mg BID for 1 or 3 months)
Study: 10335729
Drug: Primary care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary care specialty (family medicine, medicine, pediatrics, joint medicine and pediatrics)
Study: 1958451
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg three times daily with ranitidine 300 mg twice daily
Study: 1958451
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg three times daily with cimetidine 800 mg daily
Study: 31789723
Drug: Long-term medical
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term medical therapy (up to 10 years)
Study: 28650680
Drug: Finasteride, 5
Normalized name: Finasteride, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride, 5 mg per day for 4 weeks
Study: 31889148
Drug: MF59-adjuvanted trivalent
Normalized name: Influenza, adjuvanted, trivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted trivalent influenza vaccine (ATIV)
Study: 14748901
Drug: Cholesterol-lowering drug
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol-lowering drug treatment
Study: 11915781
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (200 mg of ascorbic acid twice a day)
Study: 11915781
Drug: Placebo (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (200 mg of lactose)
Study: 8307445
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride (15 mg orally thrice daily)
Study: 2661242
Drug: Sustained-release naproxen
Normalized name: naproxen Delayed Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release naproxen (1 g daily)
Study: 28541500
Drug: Oral hyperimmune
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hyperimmune bovine IgG (bIgG) raised against CFA/I minor pilin subunit (CfaE)
Study: 25395392
Drug: Oral liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral liposomal iron (30 mg/day)
Study: 25395392
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron gluconate (1000 mg total, 125 mg infused weekly)
Study: 23571819
Drug: Bifidobacterium animalis
Normalized name: Bifidobacterium Animalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium animalis subsp. lactis BB-12 (daily dose of 10^10 colony-forming units)
Study: 23571819
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (xylitol or sorbitol tablets)
Study: 18995160
Drug: Placement on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placement on a gel pillow (n = 41)
Study: 16926566
Drug: Distributed practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distributed practice regimen (weekly)
Study: 1307461
Drug: Diltiazem (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (180 to 240 mg daily, 3 to 4 tablets a day)
Study: 7774991
Drug: Nisoldipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (10 mg)
Study: 26348685
Drug: Relapses, fecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relapses, fecal incontinence, and laxative use
Study: 24525654
Drug: Sertraline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (200 mg/d)
Study: 24525654
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus Gabapentin (SERT + GBP)
Study: 15922814
Drug: Sumatriptan 50
Normalized name: sumatriptan 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 50 mg and 100 mg
Study: 10626291
Drug: LH-RH agonist
Normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LH-RH agonist leuprorelin
Study: 10626291
Drug: Cytotoxic agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxic agent treosulfane
Study: 10626291
Drug: LH-RH agonists
Normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LH-RH agonists in conventional doses
Study: 6232015
Drug: 4.0 x
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 x 10(6) units of procaine penicillin plus 1 g of probenecid
Study: 14656841
Drug: Penicillin treatment
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin treatment
Study: 6232015
Drug: Spectinomycin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spectinomycin treatment
Study: 6232015
Drug: Tetracycline (as
Normalized name: oxytetracycline (as hydrochloride)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline (as second-line treatment)
Study: 22048225
Drug: Vaporized cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaporized cannabis inhalation (3 times a day on days 2-4 and in the morning of day 5)
Study: 22048225
Drug: Sustained-release morphine
Normalized name: morphine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release morphine or oxycodone (control group)
Study: 3313202
Drug: Indomethacin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (both doses)
Study: 21817806
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (IT) aiming for BP < 120/80 mm Hg and LDL-C < 80 mg/dl
Study: 21817806
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (CT) aiming for BP < 140/90 mm Hg and LDL-C < 100 mg/dl
Study: 15553105
Drug: Emedastine difumarate
Normalized name: Emedastine Difumarate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emedastine difumarate (2 mg b.i.d.)
Study: 17229605
Drug: Loratadine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine (10 mg o.d.)
Study: 10934673
Drug: rhIL-11 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-11 (25 micrograms/kg s.c. once daily)
Study: 29503129
Drug: Failure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Failure to complete preoperative chemotherapy
Study: 18272140
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) treatment for 4 weeks
Study: 16517559
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone treatment (20 microg/kg per day) for 5 days before gonadotrophin treatment
Study: 12918077
Drug: Current oral
Normalized name: black currant oil Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current oral contraceptive use
Study: 8248274
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil as adjunctive therapy
Study: 28495197
Drug: Allopurinol 10
Normalized name: allopurinol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 10 mg/kg PO BID for 180 days
Study: 26115532
Drug: Relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy
Study: 19224814
Drug: 8% lidocaine
Normalized name: LIDOCAINE 18 g in 100 g TOPICAL CREAM [Tattoo Numbing Cream 18% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% lidocaine pump spray (Xylocaine pump spray, XPS)
Study: 28719982
Drug: Cortisone injection
Normalized name: hydrocortisone Injection
DrugBank: Cortisone (DB14681)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisone injection
Study: 29395637
Drug: D +
Normalized name: Liver Desiccated + B
Approvals — FDA: no, EMA: no, PMDA: no
Description: D + Ca + B (1200 IE vitamin D3, 800 mg Ca-carbonate, 0.5 mg B9, 50 mg B6, 0.5 mg B12)
Study: 26294207
Drug: Ornipressin (Por‐8,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornipressin (Por‐8, Ferring) solution
Study: 23082707
Drug: Colpermin (peppermint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colpermin (peppermint oil capsules)
Study: 20102596
Drug: McKenzie method
Approvals — FDA: no, EMA: no, PMDA: no
Description: McKenzie method in addition to first-line care (advice, reassurance, and time-contingent acetaminophen)
Study: 10502624
Drug: Starch based
Normalized name: THICK & EASY STARCH BASED PWDR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starch based hot stage extrusion formulation containing 300 mg anhydrous theophylline
Study: 8604729
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol solution (administered twice daily)
Study: 8604729
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol gellan (administered once daily)
Study: 6276746
Drug: Fluoride (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride (one year of treatment)
Study: 6276746
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of calcium, fluoride, and estrogen
Study: 31138725
Drug: Docetaxel 50
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 50 mg/m2, Oxaliplatin 85 mg/m2, 5-FU 2400 mg/m2 continuous intravenous infusion over 46 hours, cycles every 2 weeks
Study: 19922893
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of imatinib 400 mg
Study: 15606396
Drug: CDP870 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP870 10 mg/kg
Study: 15606396
Drug: CDP870 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP870 20 mg/kg
Study: 7898843
Drug: Intracervical prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical prostaglandin E2 (PGE2) gel
Study: 19034329
Drug: Atorvastatin (10-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10-80 mg/day)
Study: 17673219
Drug: Atorvastatin-Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin-Placebo group
Study: 12604544
Drug: 1-day treatment
Normalized name: 30 day Acne Treatment Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-day treatment with 2 g of valacyclovir twice daily for 1 day
Study: 12604544
Drug: Valacyclovir (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir (both treatment regimens)
Study: 29860335
Drug: Betaine 3300
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betaine 3300 mg orally twice daily for 10 days, then 4950 mg twice daily for 12 weeks
Study: 22757968
Drug: External Qigong
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External Qigong Therapy (EQT)
Study: 18654733
Drug: Sham Treatment
Normalized name: SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham Treatment (Control)
Study: 12494034
Drug: Nebivolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (5 mg/day) for 1 month
Study: 12494034
Drug: Hydrochlorothiazide (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (12.5 mg/day) in 5 patients
Study: 3782679
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of 0.5 mg epinephrine
Study: 8618182
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (52 micromol or 50,000 IU orally administered at birth)
Study: 2016833
Drug: Antibiotic-bonded catheters
Normalized name: SKIN BOND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic-bonded catheters (pretreated with tridodecylmethylammonium chloride and immersed in a 50-mg/mL cefazolin solution)
Study: 26393910
Drug: American ginseng
Normalized name: American ginseng
DrugBank: Panax quinquefolius whole (DB14296)
Approvals — FDA: no, EMA: no, PMDA: no
Description: American ginseng tea infusion
Study: 18214192
Drug: Zinc cream
Normalized name: CARRINGTON MOISTURE BARRIER/ZINC CREAM
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc cream
Study: 21854132
Drug: Clindamycin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (300 mg twice a day/week)
Study: 17593672
Drug: Steam inhalation
Normalized name: Leader Hot Steam Inhalation Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steam inhalation (Control)
Study: 8085464
Drug: Moclobemide (300‐450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (300‐450 mg/day)
Study: 10220121
Drug: Fluoxetine (20‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20‐40 mg/day)
Study: 2751139
Drug: 0.067 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.067 mg.kg‐1 caudal morphine
Study: 2751139
Drug: 0.10 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.10 mg.kg‐1 caudal morphine
Study: 1098499
Drug: Amodiaquine (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amodiaquine (2.0 g course)
Study: 31576433
Drug: Nivolumab 960
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 960 mg
Study: 28295989
Drug: 5 mg/ml
Normalized name: urea 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/ml liquid formulation of 6-mercaptopurine (6-MP)
Study: 28295989
Drug: 50 mg/ml
Normalized name: urea 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/ml liquid formulation of 6-mercaptopurine (6-MP)
Study: 28295989
Drug: Marketed 50
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed 50 mg 6-MP tablet
Study: 25181451
Drug: Fentanyl buccal
Normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl buccal tablet (FBT) starting titration at 200 μg
Study: 25181451
Drug: Fentanyl buccal
Normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl buccal tablet (FBT) starting titration at 100 μg
Study: 25181451
Drug: Effective doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effective doses of FBT
Study: 25181451
Drug: Fentanyl buccal
Normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl buccal tablet (FBT) at doses up to 800 μg
Study: 24490266
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg daily for 18 months)
Study: 15252267
Drug: Modafinil 400-mg
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil 400-mg once daily (7 AM) plus placebo (noon)
Study: 15252267
Drug: Modafinil (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (both dosing strategies)
Study: 11511287
Drug: Atropine 1%
Normalized name: Isopto Atropine 1% Ophthalmic Solution
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine 1% ophthalmic solution
Study: 8016009
Drug: Naftopidil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftopidil (50 mg, oral administration)
Study: 8016009
Drug: Naftopidil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftopidil (5 mg, intravenous infusion)
Study: 2648152
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml or 50 ml of fish oil (3 or 15 g of n‐3 fatty acids)
Study: 2648152
Drug: 50 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml of safflower oil (39 g of n‐6 fatty acids)
Study: 21546277
Drug: 3-day conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day conventional bowel preparation (BP) method: diet restriction, oral antibiotics, oral laxatives, and saline enemas over a 3-day period.
Study: 16859579
Drug: Subcutaneous interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous interleukin-2 (IL-2) at dose level 3: 4 MIU/m2 per day, weeks 1-4, 9-12, and 17-20 (n = 11)
Study: 9312310
Drug: Bicalutamide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide (50 mg) after food
Study: 9312310
Drug: Bicalutamide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide (50 mg) after fasting
Study: 29098249
Drug: Free dental
Normalized name: CariFree Dental Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free dental filling intervention (oral health examination and free filling of shallow and moderate caries once a year for 3 years)
Study: 23437905
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health education and training (lecture and hands-on training)
Study: 8877932
Drug: Lornoxicam 4
Normalized name: lornoxicam 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 4 mg tid (follow-up)
Study: 8877932
Drug: Lornoxicam 8
Normalized name: lornoxicam 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 8 mg bid (follow-up)
Study: 1642079
Drug: Intermediate-acting insulin
Normalized name: Intermediate-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-acting insulin twice daily (2-dose)
Study: 1642079
Drug: Preprandial regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preprandial regular insulin and intermediate-acting insulin at bedtime (4-dose)
Study: 1642079
Drug: Oral hypoglycemic
Normalized name: ORAL HYPOGLYCEMIC AGENTS,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hypoglycemic agents (before insulin treatment)
Study: 22313548
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus glycoprotein IIb/IIIa inhibitor (H-GPI)
Study: 16936707
Drug: Intranasal regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal regular human insulin (RH‐I) 40 IU acute and 4 x 40 IU/day over 8 weeks
Study: 25285572
Drug: Protease inhibitors
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitors (PI)
Study: 23484100
Drug: Fosteum (27
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosteum (27 mg natural genistein, 200 IU cholecalciferol, 20 mg citrated zinc bisglycinate)
Study: 23484100
Drug: Squadrito formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Squadrito formulation (27 mg natural genistein, 400 IU cholecalciferol, 500 mg elemental calcium)
Study: 23484100
Drug: Citracal Plus
Normalized name: Citracal Plus with Magnesium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citracal Plus Bone Density Builder (27 mg synthetic genistein, 600 mg elemental calcium, 400 IU vitamin D3, 50 mg magnesium, 7.5 mg zinc, 1 mg copper, 75 μg molybdenum, 250 μg boron)
Study: 18785964
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of triamcinolone acetonide (4 mg)
Study: 11342699
Drug: Dual-release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-release formulation of L-dopa plus benserazide
Study: 11342699
Drug: Slow-release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release formulation of L-dopa plus benserazide
Study: 7713100
Drug: Quinapril 5
Normalized name: quinapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 5 mg b.i.d.
Study: 2455118
Drug: nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine (10 mg p.o.)
Study: 10891434
Drug: Filgrastim (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgrastim (10 microg/kg daily)
Study: 1546139
Drug: Moclobemide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (150 mg t.i.d.)
Study: 1546139
Drug: Ibuprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (600 mg t.i.d.)
Study: 29676440
Drug: Bortezomib (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib (1.3 mg/m2/dose)
Study: 21750974
Drug: CHO gel
Normalized name: G-CSF (CHO cell derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO gel ingestion
Study: 18165400
Drug: Titrated oral
Normalized name: magnesium citrate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated oral misoprostol
Study: 16026367
Drug: Liraglutide 0.045
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 0.045 mg
Study: 16026367
Drug: Liraglutide 0.225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 0.225 mg
Study: 15161785
Drug: Liraglutide 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 0.75 mg